PDGFR

3 EU-approved indications of 2 drugs need a PDGFR result, in 2 tumour types, most of them in myeloid/lymphoid neoplasms with eosinophilia and TK fusions and gastrointestinal stromal tumour.

Approved indications3

DrugBiomarker requirementRegimenSettingConditions
Gastrointestinal stromal tumour1
Avapritinib
Ayvakytconditional
D842V
Monotherapy
Any line
advanced
None
Myeloid/lymphoid neoplasms with eosinophilia and TK fusions2
Imatinib
Glivec
Monotherapy
Any line
None
Imatinib
Glivec
FIP1L1-PDGFRalpha rearrangement
Monotherapy
Any line
advanced
None

PDGFR by tumour

Label wording3

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Avapritinib (Ayvakyt)
    AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.
  2. Imatinib (Glivec)
    adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
  3. Imatinib (Glivec)
    adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.